Press Release: Marker Therapeutics : Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients
Read full article »
CEO
Juan F. Vera
Marker Therapeutics is a Texas-based biotechnology firm that develops and commercializes novel T-cell therapies for the treatment of cancer.
Read more